Bio-Techne TECH Diagnostics And Genomics — Restructuring Costs Net Of Adjustments
Discontinued — last reported Q4 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept tech:RestructuringCostsNetOfAdjustments.
The official record: Bio-Techne’s 10-K, filed August 22, 2024, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's diagnostics and genomics — restructuring costs net of adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's diagnostics and genomics — restructuring costs net of adjustments?
- Bio-Techne (TECH) reported diagnostics and genomics — restructuring costs net of adjustments of $137K in Q2 2024.
- How has Bio-Techne's diagnostics and genomics — restructuring costs net of adjustments changed year-over-year?
- Bio-Techne's diagnostics and genomics — restructuring costs net of adjustments decreased by 60.8% year-over-year, from $349.75K to $137K.
- What does diagnostics and genomics — restructuring costs net of adjustments mean?
- The net cost of reorganizing business operations within the Diagnostics and Genomics segment.
- How do you interpret diagnostics and genomics — restructuring costs net of adjustments?
- An increase suggests active cost-cutting or operational realignment, while a decrease indicates stability in the segment's organizational structure.
- How does diagnostics and genomics — restructuring costs net of adjustments compare across companies?
- Commonly reported by life sciences companies undergoing M&A integration or operational optimization.